A- A A+

Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update. 

Evoy KE, Sadrameli S, Contreras J, Covvey JR, Peckham AM, Morrison MD. 

Drugs. 2021 Jan;81(1):125-156. doi: 10.1007/s40265-020-01432-7. PMID: 33215352.



Comment on "Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update". 

Bonnet U, McAnally H, Scherbaum N. 

Drugs. 2021 Mar 18. doi: 10.1007/s40265-021-01494-1. Epub ahead of print. PMID: 33738757.


Prescription of Opioids and Gabapentinoids Associated With Subsequent Overdose, Especially at High Doses and in Combination

Gabapentinoid prescriptions have increased substantially over the last 2 decades, and there is increasing evidence of a heightened risk of overdose among patients prescribed these medications, especially in combination with opioids. (Alcohol, Other Drugs, and Health: Current Evidence, Boston University, Januar-Februar 2021)


Gabapentinoid Abuse in France: Evidence on Health Consequences and New Points of Vigilance. 

Tambon M, Ponté C, Jouanjus E, Fouilhé N, Micallef J, Lapeyre-Mestre M; French Addictovigilance Network (FAN). 

Front Psychiatry. 2021 Feb 3;12:639780. doi: 10.3389/fpsyt.2021.639780. PMID: 33613345; PMCID: PMC7886797.


Pregabalin (Lyrica): reports of severe respiratory depression 

Pregabalin has been associated with infrequent reports of severe respiratory depression, including some cases without the presence of concomitant opioid medicines. Patients with compromised respiratory function, respiratory or neurological disease, renal impairment; those using concomitant central nervous system (CNS) depressants; and people older than 65 years might be at higher risk of experiencing these events and adjustments in dose or dosing regimen may be necessary. (gov.uk, Medicines and Healthcare products Regulatory Agency, UK, 18.02.2021)


Gabapentin add-on treatment for drug-resistant focal epilepsy. 

Panebianco M, Al-Bachari S, Hutton JL, Marson AG. 

Cochrane Database of Systematic Reviews 2021, Issue 1. Art. No.: CD001415. DOI: 10.1002/14651858.CD001415.pub4.


Pregabalin Misuse: Motives, Pattern, and Knowledge about Its Risks among Patients in Methadone Maintenance Treatment. 

Peles E, Sason A, Schreiber S, Adelson M. 

J Psychoactive Drugs. 2020 Dec 24:1-9. doi: 10.1080/02791072.2020.1861392. Epub ahead of print. PMID: 33357129.



Association of Gabapentinoids With the Risk of Opioid-Related Adverse Events in Surgical Patients in the United States. 

Bykov K, Bateman BT, Franklin JM, Vine SM, Patorno E. 

JAMA Netw Open. 2020 Dec 1;3(12):e2031647. doi: 10.1001/jamanetworkopen.2020.31647. PMID: 33372975.


Gabapentin for Alcohol-Related Disorders: Critical Appraisal of the Symptom-Driven Approach. 

Andrade C. 

J Clin Psychiatry. 2020 Nov 24;81(6):20f13775. doi: 10.4088/JCP.20f13775. PMID: 33238082.


Drug-Induced Gingival Overgrowth: A Pilot Study on the Effect of Diphenylhydantoin and Gabapentin on Human Gingival Fibroblasts. 

Lauritano D, Moreo G, Limongelli L, Tregambi E, Palmieri A, Carinci F. 

Int J Environ Res Public Health. 2020 Nov 7;17(21):8229. doi: 10.3390/ijerph17218229. PMID: 33171749; PMCID: PMC7664415.


Pregabalin prescribing patterns in Australian general practice, 2012-2018: a cross-sectional study. 

Schaffer AL, Busingye D, Chidwick K, Brett J, Blogg S. 

BJGP Open. 2020 Dec 1:bjgpopen20X101120. doi: 10.3399/bjgpopen20X101120. Epub ahead of print. PMID: 33172853.


Retrospective Analysis of Gabapentin for Alcohol Withdrawal in the Hospital Setting: The Mayo Clinic Experience. 

Bates RE, Leung JG, Morgan RJ 3rd, Fischer KM, Philbrick KL, Kung S. 

Mayo Clin Proc Innov Qual Outcomes. 2020 Aug 19;4(5):542-549. doi: 10.1016/j.mayocpiqo.2020.06.002. PMID: 33083703; PMCID: PMC7560568.


Pregabalin-associated movement disorders: A literature review. 

Rissardo JP, Caprara ALF. 

Brain Circ. 2020 Jun 26;6(2):96-106. doi: 10.4103/bc.bc_57_19. PMID: 33033779; PMCID: PMC7511912.


Treating anxious syndromes with pregabalin in patients with psychosis. 

Garel N, Bloom D, Joober R. 

J Psychiatry Neurosci. 2020;45(5):370. doi:10.1503/jpn.200033


Gabapentin for Post-Hospitalization Alcohol Relapse Prevention; Should Gabapentin Be Considered for FDA Approval in the Treatment of Alcohol Use Disorder?: A Case Presentation and Literature Review. 

Neuhut S. 

Cureus. 2020;12(6):e8931. Published 2020 Jun 30. doi:10.7759/cureus.8931


Is the non-medical use of pregabalin related to reward/relief craving coupled to an unbalanced opioid system?

Della Rocca F., Cosentino V., Carbone M.G., Maremmani A.G.I., and Maremmani I.

Conclusions: This paper adds to the growing body of literature suggesting that pregabalin has a non-medical use potential. When prescribing pregabalin, clinicians should consider completing a risk assessment for non-medical use, especially in patients with a Substance Use Disorder history. Therefore, pregabalin off-label prescriptions should be carefully considered.

Heroin Addiction and Related Clinical Problems, Published Ahead of Print, July 14, 2020

Is the non-medical use of pregabalin related to reward/relief craving coupled to an unbalanced opioid system?

Gabapentin-induced drug-seeking-like behavior: a potential role for the dopaminergic system.

Althobaiti YS, Alghorabi A, Alshehri FS, et al. 

Sci Rep. 2020;10(1):10445. Published 2020 Jun 26. doi:10.1038/s41598-020-67318-6


Australien. Pregabalin use found to be relatively common among people who regularly inject drugs

The use of pregabalin, a medicine for neuropathic pain, is relatively common among a sample of people who regularly inject drugs (PWID) in Australia, a new study by researchers at the National Drug and Alcohol Research Centre (NDARC), UNSW Sydney has found. 

In a sample of 905 participants from the 2018 Illicit Drug Reporting System, it was identified that 25 per cent of PWID reported using pregabalin in the previous six months.

Lead author, Dr Rachel Sutherland said; “10 per cent of the sample reported using pregabalin that was prescribed to them, while 15 per cent reported using pregabalin that was not prescribed to them.” (ndarc - National Drug and Alcohol Research Centre, Australien, 17.06.2020)


Problematic Medication With Benzodiazepines, "Z-drugs", and Opioid Analgesics.

Buth S, Holzbach R, Martens MS, Neumann-Runde E, Meiners O, Verthein U.

Dtsch Arztebl Int. 2019 Sep 13;116(37):607-614. doi: 10.3238/arztebl.2019.0607.


A study of the reasons for prescribing and misuse of gabapentinoids in prison including their co-prescription with opioids and antidepressants.

Soni A, Walters P.

Int J Prison Health. 2019 Aug 27;16(1):67-77. doi: 10.1108/IJPH-01-2019-0004.



Pregabalin induced visual hallucinations - a rare adverse reaction.

Mousailidis G, Papanna B, Salmon A, Sein A, Al-Hillawi Q.

BMC Pharmacol Toxicol. 2020 Feb 28;21(1):16. doi: 10.1186/s40360-020-0395-6.


Pregabalin Abuse in Combination With Other Drugs: Monitoring Among Methadone Patients.

Lancia M, Gambelunghe A, Gili A, Bacci M, Aroni K, Gambelunghe C.

Front Psychiatry. 2020 Feb 11;10:1022. doi: 10.3389/fpsyt.2019.01022. 


Alkoholkrankheit: Gabapentin erleichtert in Studie Abstinenz

Charleston/South Carolina –Das Antiepileptikum Gabapentin, das bei der Alkoholkrank­heit die Entzugssymptome lindert, hat in einer randomisierten kontrollierten Studie bei ausgesuchten Patienten den Alkoholkonsum gesenkt und eine Abstinenz erleichtert. Dies zeigen die jetzt in JAMA Internal Medicine (2020; doi: 10.1001/jamainternmed.2020.0249) veröffentlichten Ergebnisse. (aerzteblatt.de, 10.03.2020)


Efficacy of Gabapentin for the Treatment of Alcohol Use Disorder in Patients With Alcohol Withdrawal Symptoms: A Randomized Clinical Trial.

Anton RF, Latham P, Voronin K, et al. 

JAMA Intern Med. Published online March 09, 2020. doi:10.1001/jamainternmed.2020.0249



Trends, Patient and Prescriber Characteristics in Gabapentinoid Use in a Sample of United States Ambulatory Care Visits from 2003 to 2016.

Zhou L, Bhattacharjee S, Kwoh CK, Tighe PJ, Malone DC, Slack M, Wilson DL, Brown JD, Lo-Ciganic WH.

J Clin Med. 2019 Dec 29;9(1). pii: E83. doi: 10.3390/jcm9010083.


Electroretinographic abnormalities associated with pregabalin: a case report.

Ninomiya W, Mizobuchi K, Hayashi T, Okude S, Katagiri S, Kubo A, Masuhara N, Nakano T.

Doc Ophthalmol. 2020 Jan 3. doi: 10.1007/s10633-019-09743-1. 



Prescribed and non-prescribed gabapentin use among persons seeking inpatient opioid detoxification.

Stein MD, Kenney SR, Anderson BJ, Conti MT, Bailey GL.

J Subst Abuse Treat. 2020 Mar;110:37-41. doi: 10.1016/j.jsat.2019.12.007. 



Pain And The Use Of Gabapentinoids In German Nursing Home Residents - Results From An Analysis Based On Statutory Health Insurance Data.

Bantel C, Hoffmann F, Jobski K.

J Pain Res. 2019 Nov 22;12:3175-3184. doi: 10.2147/JPR.S221579.


Warnung der FDA zu Gabapentin und Pregabalin: Bei Risikopersonen und in der Kombi mit Opioiden droht Atemdepression

Gabapentin und Pregabalin in Kombination mit Opioiden oder mit anderen Arzneimitteln, welche das zentrale Nervensystem (ZNS) dämpfen, können lebensgefährliche Atemprobleme verursachen. Davor hat jetzt die amerikanische Arzneimittelbehörde FDA gewarnt [1]. (Medscape, 02.01.2020)


USA. FDA In Brief: FDA requires new warnings for gabapentinoids about risk of respiratory depression

“With the evolution of the opioid crisis, getting ahead of new concerns or addressing those that are already evident requires examining signs of misuse and abuse as soon as any signal emerges.
Reports of gabapentinoid abuse alone, and with opioids, have emerged and there are serious consequences of this co-use, including respiratory depression and increased risk of opioid overdose death.“ (FDA - U. S. Food and Drug Administration, USA, 19.12.2019)